Envestnet Asset Management’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Envestnet Asset Management’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,625	Closed	-$487K	–	4713
2025 Q4	$487K	Buy	+12,625	New	+$429K	﹤0.01%	3718
2021 Q2	–	Sell	-9,508	Closed	-$488K	–	3636
2021 Q1	$488K	Buy	9,508 +590	+7%	+$32.3K	﹤0.01%	2858
2020 Q4	$442K	Sell	8,918 -3,566	-29%	-$160K	﹤0.01%	2722
2020 Q3	$487K	Buy	12,484 +1,539	+14%	+$62.7K	﹤0.01%	2477
2020 Q2	$473K	Buy	10,945 +1,020	+10%	+$39K	﹤0.01%	2461
2020 Q1	$291K	Buy	+9,925	New	+$342K	﹤0.01%	2563
2018 Q3	–	Sell	-206,663	Closed	-$6.75M	–	1363
2018 Q2	$6.75M	Buy	206,663 +143,611	+228%	+$4.72M	0.02%	413
2018 Q1	$1.98M	Buy	63,052 +62,714	+18,554%	+$2.05M	0.01%	713
2017 Q4	$10K	Buy	+338	New	+$9.46K	﹤0.01%	2623
2017 Q3	–	Sell	-338	Closed	-$8K	–	2917
2017 Q2	$8K	Hold	338	–	–	﹤0.01%	2741
2017 Q1	$8K	Hold	338	–	–	﹤0.01%	2815
2016 Q4	$6K	Buy	+338	New	+$6.74K	﹤0.01%	2839

Other funds holding BBC

KCP

Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

MCM

Militia Capital Management Austin, Texas $454M AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

APW

Aurora Private Wealth Rockaway, New Jersey $158M AUM

FTUS

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Envestnet Asset Management's BBC Position: Q1 2026 in Review

Envestnet Asset Management sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q1 2026, closing a stake of 12,625 shares — an estimated $487K sold.

Envestnet Asset Management first reported a position in BBC in Q4 2016 and held it in 12 quarters. The position peaked at $6.75M in Q2 2018. 20 funds tracked by Wall St. Rank hold BBC as of Q1 2026.

Envestnet Asset Management reported no remaining Virtus Biotech Clinical Trials ETF position as of Q1 2026 after selling out during the quarter.
Envestnet Asset Management sold 12,625 Virtus Biotech Clinical Trials ETF shares in Q1 2026, an estimated $487K.
Envestnet Asset Management first reported a position in Virtus Biotech Clinical Trials ETF in Q4 2016 and held it in 12 quarters.
Envestnet Asset Management's Virtus Biotech Clinical Trials ETF position peaked at $6.75M in Q2 2018.
20 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q1 2026.

Based on Envestnet Asset Management's 13F filing for Q1 2026, filed 4 May 2026.